NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 380)
Posted On: 04/09/2021 3:37:24 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,’ said Predictive Oncology CEO Dr. Carl Schwartz. ‘Furthermore, this project is a template we can use to partner with other health care institutions and expand our AI-driven clinical models to other cancers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,’ said Predictive Oncology CEO Dr. Carl Schwartz. ‘Furthermore, this project is a template we can use to partner with other health care institutions and expand our AI-driven clinical models to other cancers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Predictive Oncology Inc. (POAI) Stock Research Links
Scroll down for more posts ▼